Request Demo
Jasper eyes next indication for hive drug, thanks to asthma success in mice
26 Feb 2024
Phase 1Clinical ResultAACR
Jasper Therapeutics' monoclonal antibody briquilimab decreased airway inflammation and the number of mast cells in the lungs of mouse models of asthma.
Jasper Therapeutics’ monoclonal antibody briquilimab is effectiairway inflammationst-cell induced anaphylaxis and asthma in mice, new data suggeasthma
Jasper Therapeuticstion and two posters abriquilimabl meeting of the American Acmast-cell induced anaphylaxisImmunasthma(AAAAI), which began Feb. 23, Jasper's researchers described experiments showing that briquilimab depletes mast cells that lead to severe allergic reactions in mice with mast cell disorders, asthma caused by allergies and drug-induced allergic reactions.
The findings point to new directions for the drug, which is currently being tested for its abilityAsthmaevent hives, formally known as urticaria.briquilimaballergic reactionsmast cell disordersasthmaallergies
“While our initial development efforts with subcutaneous briquilimab have focused on urticaria and other dermahivesical conditions, we urticariaed by its broad potential in a variety of mast cell driven diseases,” Edwin Tucker, M.D., chief medical officer at Jasper, said in a press release. “The preclinical data being generated by our research team across numerous mast cell driven diseases is critical to determining the next indication for briquilimab clinical development this year.”
Mast cells are a type of white blood cell that’s found thbriquilimabe body. At normalurticariathey help the immune system respond to pathogens and regulate other types of immune responsemast cell driven diseases activation or too many mast cells can cause allergic reactions, chronic urticaria, asthma and a range of other problems.mast cell driven diseasesbriquilimab
Briquilimab works by blocking the signaling of an enzyme called c-Kit on mast cells. C-kit protects mast cells from undergoing processes that lead to apoptosis, or cell death. Early studies of briquilimab on healthy people showed that a subcutaneous injectallergic reactionsdechronic urticariainasthmakin for up to three months.
Briquilimabical data shared in the oral presentation at the AAAAc-Kitting showed thatC-kituilimab was effective both for prophylaxis and as a treatment for asthma in mouse models. In one set ofbriquilimabs, mice that were sensitized to cockroach allergen—a known asthma trigger in humans—were treated with briquilimab 19 days before being exposed to the allergen. The treatment prevented the mice from developing inflammation in their airways, and the ones that received the drug had lower numbers of mast cells in their lungs and the skin of their backs.
In a second set of experiments, the same type of asthma mouse model developed a reactibriquilimabllergen, was treated with briquilimab, then was exposed to asthmalergen again three days later. The drug again decreased airway inflammation and the number of mast ceasthma the lung and the skin of the animalsbriquilimabey also had better lung function than untreated mice.inflammation
In the poster presentations, the researchers showasthmat a single dose of briquilimab protected mice from mast-cell inducedbriquilimabstemic anaphylaxis—a disease model of anaphylaxis where mice are sensitized to an alairway inflammationntly exposed to it—as well as anaphylaxis due to drug allergies. Only one dose was required for protection.
Jasper expects initial data from a phase 1 study on briquilimab in chronicbriquilimabs urticaria, a mast cell diseasinduced passive systemic anaphylaxis24, according to a canaphylaxisesentation given Feb. 1. The company plans to launch a second phase 1 trial on the danaphylaxisnic indudrug allergiesa, another form of the disease, in the first quarter of 2024, with data in the second half of the year.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.